array(3) {
["company_details"]=>
array(13) {
["name"]=>
string(29) "Novartis Gene Therapies, Inc."
["slug"]=>
string(19) "a26d9-us-avexis-inc"
["logo"]=>
string(84) "https://images.businessradar.com/linkedin_logos/35cea00f-69c0-468d-b166-ddd4f49dfa0c"
["description"]=>
string(639) "Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development.
Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments.
Around 108,000 people of more than 140 nationalities work at Novartis around the world.
See our community guidelines: http://bit.ly/2JnT2CP"
["address_street"]=>
string(24) "2275 Half Day Rd Ste 200"
["address_place"]=>
string(11) "Bannockburn"
["address_region"]=>
string(8) "Illinois"
["founding_date"]=>
string(10) "2010-02-28"
["website_domain"]=>
string(12) "novartis.com"
["website_url"]=>
string(24) "https://www.novartis.com"
["industry_codes"]=>
array(1) {
[0]=>
string(27) "Pharmaceutical Preparations"
}
["employee_count"]=>
int(219)
["article_count"]=>
int(7824)
}
["articles"]=>
array(9) {
[0]=>
array(7) {
["title_en"]=>
string(36) "Passes: new newsletter with hot news"
["snippet_en"]=>
string(234) "Daniel Figari joins the North American company Pfizer starting next Monday. He will be in charge of the Access and Commercial field team and after six and a half years at the Swiss Novartis, from where he leaves as Commercial manager."
["url"]=>
string(65) "https://www.pharmabiz.net/pases-nuevo-boletin-con-news-calientes/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/6489e98b-6951-4673-b977-cf04c4be2d85"
["source"]=>
string(13) "pharmabiz.net"
["publication_date"]=>
string(10) "2024-03-15"
["categories"]=>
array(1) {
[0]=>
string(12) "Staff hiring"
}
}
[1]=>
array(7) {
["title_en"]=>
string(39) "Companies hiring in 2024 - I advise you"
["snippet_en"]=>
string(108) "Here are the companies that are hiring staff. Discover new hires, new openings, job offers and how to apply."
["url"]=>
string(49) "https://www.ticonsiglio.com/aziende-che-assumono/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/cfe6790d-726a-4524-94e9-3fd7de361284"
["source"]=>
string(15) "ticonsiglio.com"
["publication_date"]=>
string(10) "2024-03-04"
["categories"]=>
array(3) {
[0]=>
string(15) "Labor Practices"
[1]=>
string(14) "Product Launch"
[2]=>
string(12) "Staff hiring"
}
}
[2]=>
array(7) {
["title_en"]=>
string(121) "Novartis is investing around 500 million euros in biopharmaceutical production in Austria, creating 350 new jobs in Tyrol"
["snippet_en"]=>
string(144) "In order to align the production network with the strategy and new technologies, Novartis announced planned investments with a focus on Austria."
["url"]=>
string(196) "https://www.ots.at/presseaussendung/OTS_20240215_OTS0131/novartis-investiert-rund-500-mio-euro-in-biopharmazeutika-produktion-in-oesterreich-und-schafft-damit-350-neue-arbeitsplaetze-in-tirol-bild"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/e3c87bb9-b82e-48f2-ba8c-69b058028fc0"
["source"]=>
string(6) "ots.at"
["publication_date"]=>
string(10) "2024-02-15"
["categories"]=>
array(10) {
[0]=>
string(22) "Business Restructuring"
[1]=>
string(18) "General Investment"
[2]=>
string(20) "Business Development"
[3]=>
string(19) "Investment Requests"
[4]=>
string(18) "Expansion & Growth"
[5]=>
string(17) "Production Issues"
[6]=>
string(12) "Staff hiring"
[7]=>
string(15) "Labor Practices"
[8]=>
string(7) "Layoffs"
[9]=>
string(25) "Business Model Resilience"
}
}
[3]=>
array(7) {
["title_en"]=>
string(75) "Charles River Laboratories Adds Reshema Kemps-Polanco to Board of Directors"
["snippet_en"]=>
string(197) "Charles River Laboratories International, Inc. (NYSE: CRL) today announced the appointment of Reshema Kemps-Polanco, Executive Vice President and Chief Commercial Officer, Novartis US, to its Board"
["url"]=>
string(163) "https://www.sharewise.com/de/news_articles/Charles_River_Laboratories_Adds_Reshema_KempsPolanco_to_Board_of_Directors_Charles_River_Lb_BusinessWireEN_20240124_2259"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/59d8b94d-57e4-4d77-b7fb-4e8b45163a7c"
["source"]=>
string(13) "sharewise.com"
["publication_date"]=>
string(10) "2024-01-24"
["categories"]=>
array(6) {
[0]=>
string(12) "Board Change"
[1]=>
string(18) "Board Compensation"
[2]=>
string(46) "Management of Legal and Regulatory Environment"
[3]=>
string(10) "Executives"
[4]=>
string(12) "Staff hiring"
[5]=>
string(20) "Corporate Governance"
}
}
[4]=>
array(7) {
["title_en"]=>
string(41) "A new CEO has been appointed to Veropharm"
["snippet_en"]=>
string(45) "Her predecessor Ivan Polyak moved to Novartis"
["url"]=>
string(88) "https://pharmvestnik.ru/content/news/V-Verofarm-naznachen-novyi-generalnyi-direktor.html"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/671ca4ca-7f6e-42e1-b488-9b7955f8b899"
["source"]=>
string(15) "pharmvestnik.ru"
["publication_date"]=>
string(10) "2024-01-24"
["categories"]=>
array(2) {
[0]=>
string(12) "Board Change"
[1]=>
string(12) "Staff hiring"
}
}
[5]=>
array(7) {
["title_en"]=>
string(50) "Novartis boss Vas Narasimhan at the diving station"
["snippet_en"]=>
string(97) "The CEO of Novartis leaves the presentation of the annual figures to his chief financial officer."
["url"]=>
string(94) "https://www.handelszeitung.ch/unternehmen/novartis-chef-vas-narasimhan-auf-tauchstation-675364"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/40f8031b-49f2-4d27-b71f-b7be1a0e674e"
["source"]=>
string(17) "handelszeitung.ch"
["publication_date"]=>
string(10) "2024-01-19"
["categories"]=>
array(6) {
[0]=>
string(12) "Board Change"
[1]=>
string(46) "Management of Legal and Regulatory Environment"
[2]=>
string(10) "Executives"
[3]=>
string(12) "Staff hiring"
[4]=>
string(24) "Quarterly/Annual Figures"
[5]=>
string(20) "Corporate Governance"
}
}
[6]=>
array(7) {
["title_en"]=>
string(37) "Eastwest Medico replaces the top post"
["snippet_en"]=>
string(98) "Eastwest Medico's former deputy director will be at the helm of the medical company from February."
["url"]=>
string(54) "https://medwatch.dk/Medico___Rehab/article16753473.ece"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/ce559de4-e8ee-43ff-9ee5-d47630a01cde"
["source"]=>
string(11) "medwatch.dk"
["publication_date"]=>
string(10) "2024-01-15"
["categories"]=>
array(4) {
[0]=>
string(12) "Board Change"
[1]=>
string(21) "Financial Performance"
[2]=>
string(12) "Staff hiring"
[3]=>
string(20) "Corporate Governance"
}
}
[7]=>
array(7) {
["title_en"]=>
string(31) "40 Under 40: Rui Yang, Novartis"
["snippet_en"]=>
string(43) "Director of marketing strategy — oncology"
["url"]=>
string(57) "https://www.mmm-online.com/40-under-40/rui-yang-novartis/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/23ff9b11-8ba9-4fc1-98c7-712f19b2938e"
["source"]=>
string(14) "mmm-online.com"
["publication_date"]=>
string(10) "2024-01-09"
["categories"]=>
array(1) {
[0]=>
string(12) "Staff hiring"
}
}
[8]=>
array(7) {
["title_en"]=>
string(107) "Ex-Novartis research head Bradner tapped to lead R&D at Amgen with Reese moving to chief technology officer"
["snippet_en"]=>
string(240) "After just more than a year off, Jay Bradner, M.D., is making a grand return to Big Pharma R&D, joining Amgen. | Changes are afoot atop Amgen's leadership team, with the company hiring Jay Bradner as chief scientific officer and R&D leader."
["url"]=>
string(122) "https://www.fiercebiotech.com/biotech/ex-novartis-research-head-bradner-tapped-lead-rd-amgen-reese-moving-chief-technology"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/110aaf84-b2eb-4c59-bb16-7c6b9484b308"
["source"]=>
string(17) "fiercebiotech.com"
["publication_date"]=>
string(10) "2023-12-14"
["categories"]=>
array(5) {
[0]=>
string(12) "Board Change"
[1]=>
string(17) "Academic Research"
[2]=>
string(5) "R & D"
[3]=>
string(10) "Relocation"
[4]=>
string(12) "Staff hiring"
}
}
}
["category_annotations"]=>
array(30) {
[0]=>
array(2) {
["name"]=>
string(12) "Stock Market"
["count"]=>
int(528)
}
[1]=>
array(2) {
["name"]=>
string(5) "Legal"
["count"]=>
int(450)
}
[2]=>
array(2) {
["name"]=>
string(11) "Acquisition"
["count"]=>
int(433)
}
[3]=>
array(2) {
["name"]=>
string(24) "Quarterly/Annual Figures"
["count"]=>
int(306)
}
[4]=>
array(2) {
["name"]=>
string(12) "Board Change"
["count"]=>
int(301)
}
[5]=>
array(2) {
["name"]=>
string(13) "Collaboration"
["count"]=>
int(241)
}
[6]=>
array(2) {
["name"]=>
string(18) "General Investment"
["count"]=>
int(238)
}
[7]=>
array(2) {
["name"]=>
string(17) "Academic Research"
["count"]=>
int(232)
}
[8]=>
array(2) {
["name"]=>
string(18) "Expansion & Growth"
["count"]=>
int(194)
}
[9]=>
array(2) {
["name"]=>
string(5) "R & D"
["count"]=>
int(189)
}
[10]=>
array(2) {
["name"]=>
string(14) "Product Launch"
["count"]=>
int(179)
}
[11]=>
array(2) {
["name"]=>
string(15) "Market Movement"
["count"]=>
int(163)
}
[12]=>
array(2) {
["name"]=>
string(8) "Epidemic"
["count"]=>
int(161)
}
[13]=>
array(2) {
["name"]=>
string(21) "Competitive Behaviour"
["count"]=>
int(160)
}
[14]=>
array(2) {
["name"]=>
string(15) "Deals & Tenders"
["count"]=>
int(142)
}
[15]=>
array(2) {
["name"]=>
string(31) "Financial Update/Profit Warning"
["count"]=>
int(133)
}
[16]=>
array(2) {
["name"]=>
string(10) "Litigation"
["count"]=>
int(130)
}
[17]=>
array(2) {
["name"]=>
string(25) "Business Model Resilience"
["count"]=>
int(125)
}
[18]=>
array(2) {
["name"]=>
string(12) "Going Public"
["count"]=>
int(119)
}
[19]=>
array(2) {
["name"]=>
string(8) "spin-off"
["count"]=>
int(114)
}
[20]=>
array(2) {
["name"]=>
string(24) "Access and affordability"
["count"]=>
int(112)
}
[21]=>
array(2) {
["name"]=>
string(46) "Management of Legal and Regulatory Environment"
["count"]=>
int(108)
}
[22]=>
array(2) {
["name"]=>
string(6) "Merger"
["count"]=>
int(98)
}
[23]=>
array(2) {
["name"]=>
string(24) "Stock Research & Ratings"
["count"]=>
int(98)
}
[24]=>
array(2) {
["name"]=>
string(12) "Staff hiring"
["count"]=>
int(85)
}
[25]=>
array(2) {
["name"]=>
string(8) "Verdicts"
["count"]=>
int(85)
}
[26]=>
array(2) {
["name"]=>
string(7) "Layoffs"
["count"]=>
int(81)
}
[27]=>
array(2) {
["name"]=>
string(15) "Business Ethics"
["count"]=>
int(80)
}
[28]=>
array(2) {
["name"]=>
string(5) "Award"
["count"]=>
int(78)
}
[29]=>
array(2) {
["name"]=>
string(10) "Divestment"
["count"]=>
int(74)
}
}
}
a26d9-us-avexis-inc
Novartis Gene Therapies, Inc.
Location
Illinois
Founded
2010-02-28
Website
https://www.novartis.com
Articles
7824 Articles
Category
Pharmaceutical Preparations
Description
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development.
Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments.
Around 108,000 people of more than 140 nationalities work at Novartis around the world.
See our community guidelines: http://bit.ly/2JnT2CP
Daniel Figari joins the North American company Pfizer starting next Monday. He will be in charge of the Access and Commercial field team and after six and a half years at the Swiss Novartis, from where he leaves as Commercial manager.
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the appointment of Reshema Kemps-Polanco, Executive Vice President and Chief Commercial Officer, Novartis US, to its Board
After just more than a year off, Jay Bradner, M.D., is making a grand return to Big Pharma R&D, joining Amgen. | Changes are afoot atop Amgen's leadership team, with the company hiring Jay Bradner as chief scientific officer and R&D leader.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
